SCHEMBL27415147

SCHEMBL27415147

COC(=O)c1cc(N=C=S)n(C)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 1/20 0.35
▸ MMP13 P45452 1/20 0.35
▸ MMP14 P50281 1/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ BAZ2B Q9UIF8 1/20 0.34
▸ KDM4E B2RXH2 3/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ HPGD P15428 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ ADORA3 P0DMS8 1/20 0.34
▸ CASP1 P29466 1/20 0.33
▸ CASP7 P55210 1/20 0.33
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ NPC1 O15118 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21603990 0.85 MMP2 (0.35) MMP2MMP13MMP14MAPK1BAZ2B
SCHEMBL28857790 0.81 MMP2 (0.40) MMP2MMP13MMP14MAPK1BAZ2B
SCHEMBL2246566 0.72 BAZ2B (0.62) MMP2MMP13MMP14MAPK1BAZ2B
SCHEMBL69696 0.72 MEN1 (0.44) MAPK1BAZ2BKDM4EALDH1A1HPGD
SCHEMBL295558 0.72 MAPK1 (0.42) MMP2MMP13MMP14MAPK1BAZ2B
SCHEMBL20455602 0.71 MEN1 (0.42) MMP2MMP13MMP14MAPK1BAZ2B
SCHEMBL24915278 0.70 MEN1 (0.42) MMP2MMP13MMP14MAPK1BAZ2B
SCHEMBL1314210 0.70 MAPT (0.41) MMP2MMP13MMP14MAPK1BAZ2B
SCHEMBL1312720 0.70 MAPK1 (0.41) MMP2MMP13MMP14MAPK1BAZ2B
SCHEMBL478715 0.70 MAPK1 (0.41) MMP2MMP13MMP14MAPK1BAZ2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 — — US disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 MMP2 1177/4885MMP13 1844/4885MMP14 1451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback